ScripChinese biotechs are racing to push back the frontiers of combination therapies for antibody-drug conjugates (ADCs), progressing multiple assets into mid-stage clinical development. Beyond the validat
ScripBiopharmaceutical companies remained on the hunt for cancer antibody-drug conjugate assets this summer, as deals revolving around ADCs accounted for five of 12 cancer-related deals, according to Biome
ScripDomestic licensing deals for homegrown innovative drugs in China posted a spike in July, as drug makers with established commercialization capabilities replenished their late-stage pipelines and resea
ScripMEI Pharma, Inc. said on 22 July that its board of directors unanimously agreed to hire a financial consultant that can help the company assess strategic alternatives to maximize the value of its ass